JAN Biotech, Inc.
Ithaca, NY Doing business as JBI
- UEI
- DKDUTDKCJQE6
- CAGE
- 71ZJ8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 95 Brown Rd #279, Ithaca, NY 14850, USA
- Website
- janbiotech.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $3,000,000 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
JAN Biotech, Inc., doing business as JBI, is a woman-owned small business based in Ithaca, New York, that develops diagnostic assays and sample collection methods for infectious disease and battlefield medical applications, operating as a prime contractor under total small business set-asides and federal Small Business Innovation Research (SBIR) grant programs.
JBI's federal footprint consists of twelve awards (100% prime, zero sub-awards) across contract and grant work. The largest single award is a $2,999,999.66 definitive contract from the Defense Health Agency, executed on September 20, 2024, under total small business set-aside for sample collection and processing methods to support battlefield wound infection diagnostics, with performance in Ithaca and ultimate completion on January 19, 2027. The company's recent grant work centers on HIV reservoir detection assays funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855). JBI is developing the HIVLATENTDETECT assay, a nonenzymatic, chemical amplification platform that delivers rapid, sensitive, and quantitative measurement of cell-based HIV RNA in antiretroviral-suppressed individuals; the company received a $300,000 Phase II SBIR grant on August 1, 2026, running through January 31, 2027. Earlier NIAID work included a pediatric HIV reservoir characterization assay (Phase I SBIR, September 1, 2023, through August 31, 2024) and a rapid COVID-19 mutation discrimination test for SARS-CoV-2 variant surveillance (September 30, 2022, through March 31, 2023).
Customer concentration sits with health and defense: the Defense Health Agency accounts for $3 million in potential value; the Army Materiel Command Research Development and Engineering Command holds two awards valued at $1.1 million combined; and the National Institute of Allergy and Infectious Diseases represents three awards (dollar value not specified individually in the source but included in combined NIAID category). The company has served eight distinct federal agencies. Combined potential value across all awards totals $4.2 million, though combined obligated dollars reach $17.8 million (425% of potential value), indicating heavy invoicing against existing awards. Three awards carrying combined potential value of $3 million face ultimate completion within the next twenty-four months and therefore present recompete opportunity.
SBA capabilities narrative
Jan Biotech, Inc. capabilities include molecular diagnostics assay and detection instrumentation R&D for highly sensitive and quantitative nucleic acid (RNA, DNA) detection, including for latent HIV and sepsis pathogen/antibiotic resistance. Other capabilities include molecular biology and genetics R&D and services, microbial and viral sterilization testing.
Quick answers
Is JAN Biotech, Inc. registered in SAM.gov?
Yes. JAN Biotech, Inc.'s SAM.gov registration is active through August 6, 2027.
How much has JAN Biotech, Inc. received in federal contracts?
Federal contracts obligated $3,000,000 to JAN Biotech, Inc. in fiscal years 2023 through 2027.
What is JAN Biotech, Inc.'s most recent federal award?
JAN Biotech, Inc.'s most recent federal grant award is Clinical assay to accurately profile and monitor the HIV-1 reservoir in chronic-treated individuals to guide… (R44AI195231), from National Institute of Allergy and Infectious Diseases (NIH), on August 1, 2026.
On GovTribe
See JAN Biotech, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors